SAGE-718
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington's Disease
Conditions
Huntington's Disease
Trial Timeline
Dec 14, 2022 → Jan 20, 2025
NCT ID
NCT05655520About SAGE-718
SAGE-718 is a phase 3 stage product being developed by Supernus Pharmaceuticals for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05655520. Target conditions include Huntington's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05655520 | Phase 3 | Terminated |
| NCT04602624 | Phase 2 | Completed |
| NCT04476017 | Phase 2 | Completed |
| NCT03787758 | Phase 1 | Completed |
Competing Products
15 competing products in Huntington's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| BN82451B + Placebo | Ipsen | Phase 2 | 49 |
| ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| WVE-120102 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| WVE-120101 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| SAGE-718 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| OMS643762 + Placebo | Omeros Corporation | Phase 2 | 47 |
| VX15/2503 + Placebo | Vaccinex | Phase 2 | 44 |